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ABSTRACT
Objectives Current UK health policy promotes 
enabling people to die in a place they choose, 
which for most is home. Despite this, patients 
with haematological malignancies (leukaemias, 
lymphomas and myeloma) are more likely to die 
in hospital than those with other cancers, and this 
is often considered a relection of poor quality 
end-of-life care. This study aimed to explore the 
experiences of clinicians and relatives to determine 
why hospital deaths predominate in these 
diseases.
Methods The study was set within the 
Haematological Malignancy Research Network 
(HMRN—www. hmrn. org), an ongoing population-
based cohort that provides infrastructure for 
evidence-based research. Qualitative interviews 
were conducted with clinical staff in haematology, 
palliative care and general practice (n=45) and 
relatives of deceased HMRN patients (n=10). Data 
were analysed for thematic content and coding 
and classiication was inductive. Interpretation 
involved seeking meaning, salience and 
connections within the data.
Results Five themes were identiied relating to: 
the characteristics and trajectory of haematological 
cancers, a mismatch between the expectations 
and reality of home death, preference for hospital 
death, barriers to home/hospice death and 
suggested changes to practice to support non-
hospital death, when preferred.
Conclusions Hospital deaths were largely 
determined by the characteristics of 
haematological malignancies, which included 
uncertain trajectories, indistinct transitions 
and dificulties predicting prognosis and 
identifying if or when to withdraw treatment. 
Advance planning (where possible) and better 
communication between primary and secondary 
care may facilitate non-hospital death.
INTRODUCTION
The UKs National End of Life Care 
Programme aimed to ensure individuals 
have more choice about where they 
die.1 The hierarchy of preferences most 
commonly reported rank home death 
first, hospice second and hospital the least 
favoured.2 While achieving home death is 
considered a key performance indicator 
and a proxy for quality end-of-life care, 
death in hospital is generally perceived as 
overly aggressive and suboptimal, along 
with emergency presentations, hospital 
admissions, chemotherapy treatments and 
intensive care input in the last weeks/days 
of life.3 4
Studies examining such issues report 
that patients with haematological malig-
nancies (leukaemias, lymphomas and 
myeloma) are more likely to receive 
aggressive end-of-life care than those 
with other cancers.58 This includes an 
increased propensity for hospital death, 
a situation identified across countries, 
regardless of healthcare systems, disease 
subtypes and patient characteristics,9 10 
reduced chance of palliative care and 
hospice referral or referral very close 
to death1114 and (in some countries) 
particularly traumatic end-of-life experi-
ences.15
Haematological malignancies are the 
fifth most common cancer in the UK.16 
These are complex diseases, and although 
they have some similarities with other 
cancers, they often require different 
management strategies. Surgical resection 
is not an option, for example, and while 
some subtypes are curable with intensive, 
toxic chemotherapy and long periods of 
hospitalisation, others are incurable from 
diagnosis but managed with intermittent 
or continuous chemotherapy.17 Taking 
such factors into account, we explored 
the experiences of clinical staff and rela-
tives of patients who had died from 
these cancers, to determine reasons why 
hospital deaths predominate.
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METHODS
The study is set within the UKs Haematological 
Malignancy Research Network (www. hmrn. org),16 an 
ongoing programme of work providing infrastructure 
for evidence-based research and aiming to improve 
the experiences of patients and their families. We 
conducted a qualitative study to elicit participants 
views, as this approach is well suited to exploring 
poorly understood phenomena.18
In-depth, semistructured interviews were carried 
out between 2012 and 2014 with 45 clinicians 
involved in the delivery of end-of-life care to patients 
with haematological malignancies, including nine 
haematologists, eight haematology nurses, six palli-
ative care/hospice doctors, seven community-based 
and seven hospital-based palliative care nurses and 
eight general practitioners (GPs). Ten relatives of 
deceased patients were also interviewed; four of these 
patients had leukaemia, four had lymphoma and two 
had myeloma. They were all aged between 66 and 
84 years at death and four were female. Recruitment 
involved purposive sampling,18 which ensured inclu-
sion of clinicians from primary and secondary care, 
as well as relatives of people with a range of diseases. 
Potential interviewees were approached via email or 
by post.
Interviews lasted 3090 min, were conducted 
privately in a hospital or university setting, or in 
relatives homes, and were audiotaped and tran-
scribed. A topic guide (see online supplemen-
tary appendix 1) was developed from existing liter-
ature and experiences of the study team, but was 
used flexibly to allow for unanticipated responses. 
Data collection continued until no new informa-
tion was forthcoming.19 Transcripts were analysed 
for thematic content. Coding and classification of 
data was inductive, following the sequential steps 
of data familiarisation by reading/re-reading tran-
scripts, development of a coding frame to apply to 
the whole data set, attribution of data to individual 
codes, collating codes into themes and interpreta-
tion through seeking meaning, salience and connec-
tions.20 To promote transparency, rigour and trust-
worthiness,20 an independent qualitative researcher 
checked and corroborated the coding of five inter-
views (around 10%).
RESULTS
Based on their experiences, none of the clinical 
participants were surprised that patients with haema-
tological malignancies were more likely to die in 
hospitals than people with other cancers. Five themes 
were identified: four relating to reasons for hospital 
deaths and one describing suggested changes to prac-
tice to facilitate non-hospital death when preferred. 
These themes are illustrated below using verbatim 
quotes.
Theme 1: characteristics and trajectory of haematological 
malignancies
It was generally agreed that hospital deaths were princi-
pally determined by the characteristics and trajectories 
of haematological malignancies. These were consid-
ered complex and uncertain, with indistinct transi-
tions between curative/life-prolonging and palliative 
approaches to care, leading to difficulties determining 
the appropriate time to initiate discussions about end-of-
life care. This uncertainty was captured in descriptions 
of trajectories, which were said to range from gradual 
decline (often punctuated by episodes of acute deterio-
ration) to sudden and unexpected death. The propen-
sity for the latter was recognised as greater in patients 
with diseases requiring urgent, intensive treatment 
(eg, acute leukaemia or aggressive lymphoma) but was 
also said to occur on a background of gradual decline, 
typically in indolent diseases following remitting/
relapsing pathways (eg, myeloma, chronic lympho-
cytic leukaemia and follicular lymphoma). Even within 
these categorisations, however, variations were found. 
Transitions were considered less dichotomous than in 
other cancers, where patients were described as being 
more likely to be discharged from individual special-
isms at specific pathway points, typically after surgery 
or failed chemotherapy.
it could be severe neutropenic sepsis, rapid 
deterioration in a situation where you are trying to 
treat (the cancer), where somebody goes from well, 
to critically unwell, to dead, and you cant plan for 
that, they suffer some sort of complication related to 
chemotherapy, so bleeding, internal haemorrhage, 
because they are profoundly thrombocytopenic
you cant plan ahead for those (events). 
(Haematologist 6)
some patients will deteriorate over days, some will 
last several months, even with acute leukaemia 
(Haematologist 4)
I do think their disease trajectory makes it more 
difficult to, eh, actually predict when theyre going 
to sort of start deteriorating, compared to other 
cancers (GP 6)
Difficulties determining prognosis were discussed by 
many interviewees. This was complicated by pathways 
that might include sudden deaths or dip up and down 
as multiple relapses and recoveries occurred. While 
the need for realistic, frank and early discussions of 
prognosis and the potential for sudden changes were 
considered crucial to advance planning, haematology 
staff described how these could sometimes only be 
initiated when patients had accepted that cure may 
not be possible. A further difficulty was identifying 
the point at which response to treatment (intensive/
non-intensive chemotherapy or supportive care) was 
no longer likely to be achieved, particularly when 
patients may have recovered previously, even from 
seemingly dire situations.
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the trouble is not knowing in advance what might 
be achieved and what might notthats quite tricky 
(Haematologist 9)
The frequent introduction of novel therapies for 
some diseases further complicated the issue of deter-
mining when to stop treatment. Treating patients 
aggressively in the last month and days of life was 
considered unavoidable, however, when this was 
being delivered with curative intent and sudden 
death occurred. In such situations, the transition 
to end-of-life care was described as absent, partic-
ularly among younger people, as emphasis was on 
saving life, often in intensive care settings. Treat-
ment was also routinely given in the terminal phase 
as an intentional strategy for disease and symptom 
control, and to maintain quality of life for as long 
as possible. Non-haematology specialists considered 
this approach overly aggressive, however, believing 
that it occurred due to reluctance on the part of 
(some) haematologists to discuss withdrawing treat-
ment and possible death, factors cited as impeding 
decision-making and advanced planning.
some consultants treat, treat, treat (Palliative nurse 
5)
I think haematology want to keep patients going as 
long as possible and they dont want to break that 
bad news (Palliative nurse 1)
Overtreating of certain groups of patients, such as 
those with acute myeloid leukaemia (AML), was 
acknowledged by some haematologists.
I personally think we treat far too many people 
far too aggressively, that the thrust of AML is 
completely wrong, if the patient is over 60 or 70 
you are never going to cure them. Taking a more 
palliative, quality of life approach would probably 
be better (Haematologist 6)
Some respondents alluded to co-dependency 
between haematologists and their patients, describing 
haematologists reluctance to give up exploring 
treatment options. In this context, patients contrib-
uted to the impetus for ongoing treatment and hospi-
talisation, being desperate to try anything in the 
hope of achieving cure or postponing death. Patients 
were said to associate this with (possibly false) hope 
for continuing life and discharge from haematology 
to home or hospice with imminent death.
it might be quite hard to be impassive you 
[haematologist] think, well, weve pulled them back 
from a similar situation before, maybe we can do it 
againand that has some impact on your ability to 
let goin the context of withdrawing treatment
up to that point, you might have always been the 
guy who had the next treatment ready, the next idea, 
if this doesnt work, well do thisand that has on 
occasion worked and helped improve quality of life 
or prognosis (Haematologist 4)
he was a fighting spirithe wanted to go on 
being treatedhe wanted treatment to the end 
(Haematology nurse 7)
she wanted anything, if it could prolong things, if it 
could give her more time, then she wanted to have 
it (Relative 9, concerning deceased wife)
we really wanted him to go to the hospice as he was 
dying, fading away and he would not have ithe 
chose to stay on the wardhe wanted to cling on to 
the blood teststhe reassurance he was still being 
watched (Haematologist 1)
Theme 2: mismatch between the expectations and reality 
of home death
Patients and relatives limited knowledge and some-
times unrealistic expectations about end-of-life 
processes, and the sudden onset of distressing symp-
toms, such as bleeding and sepsis, were said to poten-
tially precipitate a shift in preference away from home 
towards hospital death.
the reality of somebody dying at home can be very, 
very difficult and very different to the home sweet 
home image you might have (Haematology nurse 
4)
he would have continued at home if he hadnt 
started coughing up blood and couldnt get his 
breath (Relative 5spouse died in the hospital)
As a consequence, another reported cause of hospital 
death was the frequency with which patients bounce 
back into hospital due to sudden deterioration and 
distressing symptoms. Emergency calls from rela-
tives, GPs or out-of-hours doctors were cited as major 
reasons for readmissions, as ambulance staff (often 
lacking information about preferences) were said to 
routinely transport patients to Accident and Emer-
gency (A&E), resulting in hospital admission.
the problem is, if theyre bleeding and the relatives 
panicking, they call 999, obviously they end up 
going to A&Ethen they end up with the problem 
of inappropriate treatments theyre [emergency 
services] not aware of the fact that somebodys got 
leukaemia in the terminal phasewe [primary care 
clinicians] need to make sure that we communicate 
well with A&E and the ambulance service, the 
paramedics, so they know exactly what theyre 
dealing with (GP 8)
Theme 3: preference for hospital death
The close relationship between haematology staff, 
patients and their relatives was often discussed and was 
perceived to lead to preferences to remain in hospital 
at the time of death. This bond was considered a posi-
tive consequence of ongoing contact between the indi-
viduals involved over prolonged time periods. It was 
described as arising from experiences of exemplary 
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care, in a setting often regarded as a second home, 
and associated with feelings of safety and secu-
rity. Consequently, situations were described where 
remaining in the haematology ward, in a familiar envi-
ronment with well-known staff, was said to be prefer-
able to moving to a palliative care or hospice setting 
where new relationships would need to be built, often 
over short periods of time.
Some haematology staff shared similar sentiments, 
describing how transferring their patients to commu-
nity staff they did not know for end-of-life care could 
feel like abandoning them. These interviewees also 
described a certain satisfaction in being able to provide 
terminal care for patients they had known a long time, 
although this was sometimes countered by concerns 
about capacity (eg, staff time and availability of a 
private room).
youve been there for the relatives, for the carers 
and you want to see all that through the difficulty 
sometimes is that by transferring somebody 
purely to palliative care, you almost feel as if youre 
washing your hands of them (Haematology nurse 4)
I think that a lot of it is building relationships 
again, and the way we work is that we, we see them 
at diagnosis and we doall the chemotherapy 
treatments, so we get a really close bond and then 
they, theyre always coming back to clinic and were 
seeing them so if they relapsed, it would be us that 
they would see again .so really in the end weve 
got kind of years of quite a strong bond with our 
patients and I think thats the hard thing then is that 
when they do come towards the end I think they 
feel that they want to stay with us (Haematology 
nurse 7)
theres only two people on nights for 20 patients, 
and if youve got someone whos dying its awful. 
During the day isnt so bad you have five nurses 
on, in the morning, and you go to two at night. So 
you know, its a big difference. (Haematology nurse 
1)
Haematology doctors and nurses often questioned 
whether a good death could only occur at home, 
proposing instead that patients and their familys 
needs for physical and emotional support could be 
effectively met through hospital haematology services, 
with input from palliative medicine as required, and 
that this may be entirely appropriate.
the current rhetoric that the only good death is a 
home death is absolute nonsense its wherever 
the patients needs are best met some patients 
get to know the nursing staff pretty well, and for 
them, its much nicer for them to go back to a 
ward where they know all the staff, than it is to go 
somewhere else or even to struggle in their home
so it may be their choice that theyre coming in to 
die, and I dont think we should deny them that 
just because the Government has a bee in its bonnet 
about people must die at home and I can see in 
haematology patients who have been coming in and 
out of a ward for years a hospital death may be an 
appropriate deathand it may be done very well, 
actually (Haematologist 1)
Some differences were identified between haema-
tology practitioner perceptions and those of other 
clinicians and some relatives, however, with the latter 
being most likely to cite home as the expected end-of-
life preference.
Theme 4: barriers and facilitators to home or hospice death
A number of practical barriers to non-hospital death 
that were specific to patients with haematological malig-
nancies were identified. Some generalists expressed 
unease about managing haematology patients at home, 
either because they thought they themselves lacked 
knowledge about what were perceived as complex 
diseases, or because they considered that distressing 
symptoms, such as bleeding, were a barrier to death 
at homea view shared by some haematology staff. 
Others, however, reported the relative infrequency 
with which such symptoms occurred, and did not 
consider the end-of-life care needs of haematology 
patients to differ much from that of people with other 
conditions.
bleeding would be the big one for patients with 
HMyou would have to have robust family and 
carers to cope with that (Palliative doctor 5)
the last patient that I tried to manage at home, she 
had a big, uh, GI bleed at the end of the life, so she 
came in, because of that, cause her husband could 
not cope with that (Haematology nurse 5)
weve got dedicated district nurses, that, I would 
have every confidence, they could look after that
haematological malignancy may, may be more 
dramatic, but you can get just as ill with other 
malignanciespain, bleeding, breathlessness, 
agitation, confusion, all those things you get with 
any cancerand you get with the haematological 
malignancy patients. Interviewer: So its not actually 
that different from looking after patients with other 
cancers. Um, no, not in terms of providing end of 
life care (GP 3)
Due to the potential for rapid deterioration and death 
within hours or days, home-discharge (when preferred) 
could be required at short notice. While some hospi-
tals had systems in place to organise this (eg, integrated 
discharge teams), others did not. In the latter case, the 
haematology nurses found such discharges could be 
time-consuming and frustrating, particularly if systems 
could not be put in place before the patient became 
too ill to be moved. Similarly, hospice beds were not 
always available at short notice, and inconsistencies in 
policies concerning the delivery of transfusions (often 
said to be required to maintain quality of life) repre-
sented barriers to referral.
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when you are trying to get someone home, it 
takes up an incredible amount of timephone the 
hospice, phone the district nurses, get stuff in place, 
like a bed, sometimes you dont have time to do 
itand the patient is deteriorating in front of your 
eyessometimes, a lot of the time, you have to stop 
and say, you are too unwell to go home now. I think 
thats one of the reasons people dont die at home 
(Haematology nurse 1)
the blocking point for us is that often there is no bed 
in the hospice, or they cant deal with transfusion 
needs (Haematology consultant 5)
Inadequate communication across the primary/
secondary care interface was regarded as a significant 
challenge to home death by GPs and community palli-
ative care nurses. Haematological malignancies were 
described as cancers that were generally managed 
solely by haematologists in the hospital setting, with 
patients being encouraged to contact the haematology 
unit (rather than their GP) as the first port of call 
for advice about their disease. Although GPs received 
correspondence about hospital appointments and 
admissions, this process was said to cause them to lose 
contact with their patients, and know little of their 
likely prognosis.
we can feel out of the loop.you dont know 
whats going on (GP 4)
In such cases, GPs were sometimes not aware that fast-
track hospital discharge may be required to facilitate 
home death, and they typically felt that they were 
left with little time to develop relationships with the 
patient or their relatives before the patients death.
its usually two faxes, one for us (GP) and one for 
the district nurses, to say this patient is coming 
homeweve done this, weve done that, theres no 
more active treatment, they will needand theres a 
list of stuff, and thats sometimes the first we know 
of it (GP 1)
Other important barriers to home death were reported 
that are likely to be common across other cancers, 
including gaps in community nursing services (partic-
ularly overnight), patients living alone and/or without 
lay carer's support and the ability of lay carers to manage 
at home, particularly in circumstances involving young 
children, or lay carers who were themselves frail or 
unwell.
Analysis of data from relatives interviews revealed 
that the patients who had died at home (table 1), in 
line with their wishes, held strong preferences about 
place of care and death, which were in accord with 
relatives preferences.  They also had a good level 
of support from family members (who were said to 
have actively intervened to promote their wishes and 
ensure these were achieved), had symptoms that could 
be managed at home, considered nursing services 
support to be adequate and/or had the financial means 
to buy in private carers to plug gaps, and had a GP 
who was closely involved in their care. Again, many of 
these factors are likely to be common across patients 
with other cancers.
Theme 5: suggested changes to practice to support home 
or hospice death
Interviewees suggested a number of changes that 
they considered could facilitate home/hospice death. 
Early initiation of frank conversations about prog-
nosis (where possible), alongside timely integra-
tion of haematology and palliative care specialists 
(including at diagnosis or while active treatment was 
still ongoing), was considered important by all inter-
viewees. While some discussed difficulties identifying 
the appropriate time to involve palliative care clini-
cians, others considered mutual understanding of their 
roles as underpinning timely referrals. Cited methods 
of promoting joint working included co-location of 
facilities, shared clinics and integration of palliative 
care staff into haematology multidisciplinary team 
Table 1 Patients’ (reported) and relatives’ (expressed) PPD, changes over time and actual place of death
Study ID Patient’s PPD Relative’s PPD
Patient’s change of 
preference Relative’s change of preference
Actual place of 
death
  1 Home Hospice He ‘couldn’t have cared’ (after 
sudden deterioration)
Hospital death was ‘peaceful’ and care 
was good
Hospital
  2 Hospice Home Home Unchanged Home
  3 Not stated Not stated Not stated Not stated Home
  4 Not stated Hospital Not stated Not stated Hospital
  5 Hospice Home Not stated ‘with hindsight, hospital was the right 
place’ (after sudden deterioration)
Hospital
  6 Not stated Home Not stated Unchanged Home
  7 Home Home Unchanged Unchanged Home
  8 Home Home Unchanged Unchanged Home
  9 Home Home Unchanged Unchanged Home
  10 Home Unsure Not stated Hospital was the ‘right place’ Hospital
PPD, preferred place of death.
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meetings. Interviewees described many such systems 
as already being in place, and most reported increasing 
collaboration over time.
were now in the same buildingat the moment 
on the (palliative care) inpatient unit weve got two 
people with haematological malignancies here now 
and Ive got one or two on the booksin the past 
my experience was that we got very few referred
now were all in one unitwere getting referrals 
through (Palliative doctor 5)
there is merit I think to look at scoping the need or 
benefits of having a joint clinic between palliative 
care and haematology to help identify those 
patientswho need palliative input (Palliative 
nurse 5)
over the time Ive worked in this area, over 9 years, 
I think that its changing, haematologists are more 
readily involving palliative care at an earlier stage 
(Palliative nurse 3)
Another common suggestion was for consistent, clear 
and detailed documentation of end-of-life discussions, 
and electronic transfer of this across care interfaces. 
Primary care practitioners discussed the Gold Stan-
dards Framework21 (a system that many of the study 
hospital-based clinicians were unaware of) and how 
use of the surprise question (would you be surprised if 
this patient were to die in the next few months, weeks, 
days?), may help to identify patients nearing end of 
life.22 It was largely agreed that such a system would 
facilitate prognostic estimations in secondary care, and 
if communicated to primary care, may enable fast-
track discharge. It was considered limited, however, in 
the context of sudden death.
communication between the teams, secondary 
and primary care, and also of course from the 
haematology team as well, is essentialwe need a 
clear indicationthis is where we are and what we 
are or not doing, and this is what we might or might 
not be able to do with this patientis a key, a key 
thing I think (Palliative doctor 4)
oncologists, when theyre writing to the GPs with 
clinic letters there is now a drive for them to say, 
it would be appropriate for you to put this patient 
on your Gold Standards Framework registerum, 
thats actually happening, Ive seen it (Palliative 
doctor 5)
Other suggestions include early mobilisation of 
community-based services (district, Marie Curie and 
Macmillan nurses and hospice at home services), and 
if preference is for home care and death, the setting 
up of mechanisms for anticipatory prescribing and 
arranging the installation of equipment (eg, hospital 
beds, syringe drivers).
DISCUSSION
Hospital deaths among patients with haematolog-
ical malignancies were largely determined by the 
characteristics and pathways of these diseases, which 
resulted in uncertain trajectories, indistinct transitions 
and difficulties predicting prognosis and identifying if 
or when to withdraw treatment, factors which compli-
cated advance planning. Delivery of care defined as 
aggressive in other studies,58 such as treatment close 
to the time of death, was often considered unavoid-
able and appropriate in the context of blood cancers, 
for both disease and symptom control. This suggests 
that the criteria currently used to assess end-of-life 
care may not be appropriate for haematological malig-
nancies, a notion alluded to by others, but not always 
agreed on.2325
Much literature has emerged in recent years, both 
promoting home death and questioning whether this 
is always preferable to hospital death.2628 We found 
patient/relative choice to be commonly cited as the 
reason for hospital death and this explains to some 
extent the large proportions of deaths previously 
reported in this setting across disease subtypes, and 
not only among those who die suddenly.10 The desire 
among haematology doctors and nurses to provide 
terminal care for patients they have known and treated 
for many years is understandable, particularly among 
experienced staff who are skilled in managing end-of-
life issues, and in situations where specialist palliative 
care support is also available.
The close relationship between haematologists and 
their patients undoubtedly underpins the concepts of 
co-dependency and the co-production of optimism, 
which stem from the emotional and relational ties that 
develop within medical contexts.29 30 This is partic-
ularly important in blood cancers, where the most 
common barriers to quality end-of-life care have been 
described as unrealistic patient and clinician expec-
tations, and clinician concerns about taking away 
hope.25 Complex situations have been described where 
haematologists must attempt to maintain hope while 
supporting patients to aim for cure, yet concurrently 
prepare for death.31
Identifying the optimum time to discuss prognosis 
and end-of-life preferences with haematology patients 
and their families is crucial, yet often difficult to 
achieve due to the propensity for sudden deterioration 
and unexpected death. More accurate prognostic data, 
frank early discussions (possibly near to the time of 
diagnosis) about potential outcomes (good and bad) 
and the appropriateness of further treatment may 
generate more realistic expectations. Such discussions 
are, however, likely to be difficult for some people, 
regardless of timing and the communication skills of 
the clinician; and may be impossible if patients die 
unexpectedly.
Although haematologists have been criticised in 
the past for lacking integration with palliative care 
services,17 we were informed of significant and 
increasing co-working between these specialities, often 
from diagnosis. Death in the hospice setting posed 
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particular difficulties, however, largely due to a lack 
of available beds when needed and inconsistencies 
in service provision (ie, availability of blood product 
transfusions and antibiotics).
Fast-track hospital discharges were particularly 
challenging for primary care practitioners to manage. 
Our findings highlight the importance of sharing 
information across interfaces as a prerequisite for 
informed decision-making by GPs, nurses, out-of-
hours doctors and paramedics and the prevention of 
unwanted hospital (re)admissions. Communication 
of broad life expectancy estimates (eg, identification 
of patients who might be expected to die within 6 
to 12 months) might also enable primary care prac-
titioners to facilitate discussions about end-of-life 
choices, and prepare for the possibility of home 
death, should this be preferred. Decision-making 
could also be supported by the widespread roll out 
across care settings of electronic systems that facil-
itate the recording of preferences. Electronic Palli-
ative Care Coordinating systems32 have been intro-
duced since our data collection took place, which 
may address this need, although views on their 
utility are mixed.33
Strengths and weaknesses
As far as we are aware, this is the first UK study to 
explore determinants of hospital deaths in patients 
with blood cancers. Qualitative data were gath-
ered from a range of key informants (healthcare 
practitioners and relatives of deceased patients) 
and a broad range of views and experiences was 
obtained, facilitating cross-comparison of perspec-
tives between groups of participants and the identi-
fication of challenges across healthcare settings. We 
acknowledge that including bereaved relatives may 
provide a limited understanding of patient pref-
erences, and that non-inclusion of relatives from 
minority ethnicity groups, whose perspectives may 
differ due to cultural factors, could limit generalis-
ability. Additionally, our study drew on information 
provided by the relatives of patients aged 6684; 
the experiences of relatives of younger or older 
patients may differ. Due to the relatively under-re-
searched nature of the topic, however, these issues 
may be considered less salient than that of sensi-
tising readers to novel information.20
Comparison to other studies
Although we did not identify any other studies 
specifically examining determinants of hospital 
deaths across such a wide range of interviewees, 
our findings are similar to those of other UK and 
non-UK studies examining end-of-life care more 
generally.23 34 35 These studies also highlighted 
differences between haematological malignancies 
and other cancers, often caused by disease factors 
(eg, complex transitions and difficulties estimating 
prognosis), and resulting in late end-of-life discus-
sions and hospital death. They also note the close 
relationships that develop between haematologists 
and their patients, and the variable impact this may 
have on discussing and determining approaches 
to care at the end of life, including reluctance to 
dispel hope and feelings of abandonment if patients 
are handed over to palliative care services. While 
other studies also reported patient preferences to 
remain in the hospital to die,36 the notion that it was 
possible to provide terminal care for haematology 
patients at home was also supported,37 38 including 
the possibility of successfully managing issues such 
as bleeding in the home setting.
Recent studies from the USA report some haema-
tology practitioners viewing palliative care involve-
ment with distrust, perceiving it to be antithetical to 
cancer care, concerned only with end-of-life care, 
and contraindicative to ongoing treatment; the 
name of the service was also considered a barrier 
to referral.39 40 With the exception of limitations to 
the supportive treatment offered in hospice settings 
(eg, transfusions), we mainly found evidence of 
increasing collaboration and co-working. This is 
supported in a UK study that identified universally 
favourable reports among haematologists about 
palliative care services.35 Possible reasons for such 
variations include differing perceptions and prac-
tices between countries.
CONCLUSION
Hospital deaths were largely determined by the char-
acteristics of haematological malignancies, which 
included uncertain trajectories and indistinct transi-
tions, and difficulties predicting prognosis and iden-
tifying if or when to withdraw treatment. Although 
end-of-life care for patients with these diseases is 
often considered aggressive compared with other 
cancers, the reasons for this may be appropriate and 
unavoidable. Nonetheless, there is scope to improve 
practice, including: better information about prog-
nosis (where possible), earlier, frank discussions 
about likely outcomes and improved communica-
tion between care settings.
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